Methods and Compositions for the Clinical Derivation of an Allogenic Cell and Therapeutic Uses

Abstract

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

What is claimed is: 
     
         1 . A method of treatment, comprising;
 administering isolated cells to a subject to treat a medical condition selected from COPD, diabetes, ischemia, osteoarthritis, orthopedic damage, liver damage, chronic refractory angina, erectile dysfunction, herniated disks, congestive heart failure, asthma, emphysema, wounds, acute radiation syndrome, autoimmune disorders, ischemic organ beds, graft vs. host disease, or a combination thereof, wherein the isolated cells are obtained, without enzymes, from a subepithelial layer of a mammalian umbilical cord tissue capable of self-renewal and culture expansion;   wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105; and   wherein the isolated cell does not express NANOG and at least five cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.   
     
     
         2 . The method of  claim 1 , wherein the isolated cell expresses CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, and CD105. 
     
     
         3 . The method of  claim 1 , wherein the isolated cell does not express CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, and HLA-DR. 
     
     
         4 . The method of  claim 1 , wherein the isolated cell is positive for SOX2. 
     
     
         5 . The method of  claim 1 , wherein the isolated cell is positive for OCT4. 
     
     
         6 . The method of  claim 1 , wherein the isolated cell is positive for SOX2 and OCT4. 
     
     
         7 . The method of  claim 1 , wherein the wherein the isolated cell is capable of differentiation into a cell type selected from the group consisting of adipocytes, chondrocytes, osteocytes, cardiomyocytes, endothelial cells, and myocytes. 
     
     
         8 . The method of  claim 1 , wherein the isolated cell produces exosomes expressing CD63, CD9, or CD63 and CD9. 
     
     
         9 . An isolated cell obtained from a subepithelial layer of a mammalian umbilical cord tissue capable of self-renewal and culture expansion;
 wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105; and   wherein the isolated cell does not express NANOG and at least five cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.   
     
     
         10 . The isolated cell of  claim 9 , wherein the isolated cell expresses CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, and CD105. 
     
     
         11 . The isolated cell of  claim 9 , wherein the isolated cell does not express CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, and HLA-DR. 
     
     
         12 . The isolated cell of  claim 9 , wherein the isolated cell is positive for SOX2. 
     
     
         13 . The isolated cell of  claim 9 , wherein the isolated cell is positive for OCT4. 
     
     
         14 . The isolated cell of  claim 9 , wherein the isolated cell is positive for SOX2 and OCT4. 
     
     
         15 . The isolated cell of  claim 9 , wherein the wherein the isolated cell is capable of differentiation into a cell type selected from the group consisting of adipocytes, chondrocytes, osteocytes, cardiomyocytes, endothelial cells, and myocytes. 
     
     
         16 . The isolated cell of  claim 9 , wherein the isolated cell produces exosomes expressing CD63, CD9, or CD63 and CD9. 
     
     
         17 . A method of treating COPD, comprising:
 administering a COPD effective active agent intravenously to a subject to deliver the COPD effective active agent to a lower half of the subject's lung; and   administering the COPD effective active agent in an aerosolized form to the subject via ventilation to deliver the COPD effective active agent to an upper half of the subject's lung.   
     
     
         18 . The method of  claim 17 , wherein the COPD effective active agent includes stem cells. 
     
     
         19 . The method of  claim 18 , wherein the stem cells include the cells of  claim 9 . 
     
     
         20 . The method of  claim 18 , wherein the stem cells are aerosolized with an aerosolizer to a size of from about 6 to about 200 microns. 
     
     
         21 . The method of  claim 17 , wherein the COPD effective active agent includes a member selected from the group consisting of exosomes, cell lysates, protein extracts derived from cell culture, and combinations thereof.